Unlisted Shares
PharmEasy
PharmEasy (Unlisted)
Verified Unlisted CompanyOff-market Transfer · NSDL / CDSL
About PharmEasy
PharmEasy is India's leading digital healthcare platform. It provides information, consultations, diagnostic tests, medicines, healthcare packages, and more from registered and trusted pharmacies, leading diagnostic laboratories, and trusted doctors across India. The company started in 2015 with the mission to make healthcare accessible, affordable, and transparent.
Share Details
| company Name | PharmEasy (Unlisted) |
| indicative Unlisted Share Price | ₹9 |
| market Capitalization | ₹10445 Crore |
| lot Size | 1000 |
| 52 Week High | ₹5008 |
| 52 Week Low | ₹6.25 |
| face Value | ₹10 |
| book Value | 1.52 |
| pe Ratio | N/A |
| pb Ratio | 3.26 |
| debt To Equity | 0.62 |
| return On Equity | -48.05 |
| total Outstanding Shares | 167032304 |
| isin | Not Available |
| depository | NSDL & CDSL |
| pan | AADCP201E |
| cin | U85100MH2015PLC266025 |
| rta | Link Intime |
Income Statement (Profit & Loss) (₹ in Crore)
| Particulars | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 5,729 | 5,864 | 5,684 | 5,872 |
| EBITDA | -2,607 | -121 | -646 | -981 |
| PBT | -3,911 | -5,106 | -2,522 | -1,387 |
| Net Profit / Loss (PAT) | -3,999 | -5,211 | -2,533 | -1,387 |
| EPS | -8.51 | -8.48 | -3.9 | -2.26 |
Key Financial Ratios (Last 3–5 Years)
| Ratio | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Operating Profit Margin (%) | -45.5 | -2.06 | -11.36 | -16.71 |
| Net Profit Margin (%) | -69.8 | -88.86 | -44.56 | -23.62 |
| Earning Per Share (Diluted) | -8.51 | -8.48 | -3.9 | -2.26 |
Financial Annual Report Summary
PharmEasy has shown massive revenue growth but continues to incur losses due to heavy investments in expansion, technology, and market share acquisition in the highly competitive digital pharmacy sector.
Why Invest in PharmEasy
- Market leader in digital pharmacy space.
- Significant revenue scale but ongoing losses due to growth investments.
- High cash burn typical for fintech/healthtech unicorns.
Balance Sheet - Assets (₹ in Crore)
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Fixed Assets | 1,025 | 912 | 736 | 682 |
| CWIP | 7.8 | 4 | 3.8 | 11 |
| Investments | 438 | 352 | 329 | 179 |
| Trade Receivables | 881 | 905 | 708 | 870 |
| Inventory | 761 | 688 | 558 | 554 |
| Other Assets | 6,305.2 | 5,405 | 8,081.4 | 4,698 |
| Total Assets | 11,398 | 6,255 | 8,390 | 6,977 |
Balance Sheet - Liabilities & Equity (₹ in Crore)
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Share Capital | 476.2 | 614.2 | 649.8 | 694.3 |
| FV | 1 | 1 | 1 | 1 |
| Reserves | 6,408.3 | 1,622 | 1,158 | 2,577 |
| Borrowings | 2,665 | 1,932 | 2,378 | 1,026 |
| Trade Payables | 459 | 413 | 415 | 426.5 |
| Other Liabilities | 1,381.5 | 1,265 | 2,081 | 1,241.5 |
| Total Liabilities | 11,398 | 6,255 | 8,390 | 6,977 |
Liabilities Breakdown & Balance Sheet Insights
Balance Sheet Insights
Debt to Equity ratio of 0.62. Significant cash burn funded by equity raises.
Liabilities Breakdown
Debt to Equity ratio of 0.62.
Additional Insights
Heavy investment in technology, inventory, and expansion leading to high asset base.
Cash Flow Insights
- High cash burn from operations typical for growth-stage healthtech.
- Funded through equity and debt financing.
Shareholding Pattern
Recent
Promoter: High
Institutional: Low
Public: Low
Promoters & Management
Founded by Dharmil Sheth, Dhaval Shah, and others with strong healthcare and tech background.
Key Management
Not Available on page
Registrar & Transfer Agent (RTA)
Registrar: Link Intime
Website: https://linkintime.co.in/
Management Analysis
Focus on building India's largest digital healthcare ecosystem with omnichannel presence.
Frequently Asked Questions About PharmEasy
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.